- Home
- KFRC vs XOMAO Comparison
KFRC vs XOMAO Comparison
Compare KFRC & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFRC
- XOMAO
- Stock Information
- Founded
- KFRC 1962
- XOMAO N/A
- Country
- KFRC United States
- XOMAO United States
- Employees
- KFRC N/A
- XOMAO 13
- Industry
- KFRC Professional Services
- XOMAO Biotechnology: Pharmaceutical Preparations
- Sector
- KFRC Consumer Discretionary
- XOMAO Health Care
- Exchange
- KFRC Nasdaq
- XOMAO Nasdaq
- Market Cap
- KFRC N/A
- XOMAO N/A
- IPO Year
- KFRC 1995
- XOMAO N/A
- Fundamental
- Price
- KFRC $56.21
- XOMAO $25.55
- Analyst Decision
- KFRC Buy
- XOMAO
- Analyst Count
- KFRC 3
- XOMAO 0
- Target Price
- KFRC $66.67
- XOMAO N/A
- AVG Volume (30 Days)
- KFRC 105.5K
- XOMAO N/A
- Earning Date
- KFRC 02-03-2025
- XOMAO N/A
- Dividend Yield
- KFRC 2.70%
- XOMAO N/A
- EPS Growth
- KFRC 9.19
- XOMAO N/A
- EPS
- KFRC 2.90
- XOMAO N/A
- Revenue
- KFRC $1,424,973,000.00
- XOMAO N/A
- Revenue This Year
- KFRC N/A
- XOMAO N/A
- Revenue Next Year
- KFRC $0.84
- XOMAO N/A
- P/E Ratio
- KFRC $19.37
- XOMAO N/A
- Revenue Growth
- KFRC N/A
- XOMAO N/A
- 52 Week Low
- KFRC $52.96
- XOMAO N/A
- 52 Week High
- KFRC $74.79
- XOMAO N/A
- Technical
- Relative Strength Index (RSI)
- KFRC 35.45
- XOMAO 52.86
- Support Level
- KFRC $58.67
- XOMAO $25.31
- Resistance Level
- KFRC $60.03
- XOMAO $25.69
- Average True Range (ATR)
- KFRC 1.48
- XOMAO 0.10
- MACD
- KFRC -0.54
- XOMAO 0.03
- Stochastic Oscillator
- KFRC 10.31
- XOMAO 61.70
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.